New drug cocktail shows promise for three tough cancers
NCT ID NCT05077709
First seen Apr 14, 2026 · Last updated May 25, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs (IO102-IO103 and pembrolizumab) as the first treatment for people with advanced lung, head & neck, or bladder cancer that has spread. The goal was to see if the combo could shrink tumors and delay cancer growth. A total of 63 patients took part in this early-stage trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Guys and St Thomas Hospital
London, United Kingdom
-
Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, 50009, Spain
-
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
-
Hospital Universitari de Girona Doctor Josep Trueta
Girona, 17007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
Seville, Sevilla, 41009, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology)
Barcelona, 08916, Spain
-
Mid Florida Hematology and Oncology Center
Orange City, Florida, 32763, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
University of California San Diego
San Diego, California, 92093, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States
-
Velindre Cancer Center
Cardiff, CF14 2TL, United Kingdom
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.